| Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H) LK Csatary, RW Moss, J Beuth, B Torocsik, J Szeberényi, T Bakács Anticancer research 19 (1), 635-638, 1999 | 149 | 1999 |
| The cancer industry: the classic expose on the cancer establishment RW Moss Equinox Press, 1996 | 134* | 1996 |
| Sonodynamic and photodynamic therapy in advanced breast carcinoma: a report of 3 cases X Wang, W Zhang, Z Xu, Y Luo, D Mitchell, RW Moss Integrative Cancer Therapies 8 (3), 283-287, 2009 | 125 | 2009 |
| Do antioxidants interfere with radiation therapy for cancer? RW Moss Integrative cancer therapies 6 (3), 281-292, 2007 | 118 | 2007 |
| Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? RW Moss Integrative cancer therapies 5 (1), 63-82, 2006 | 114 | 2006 |
| Questioning chemotherapy RW Moss Equinox Press, 1995 | 106 | 1995 |
| Cancer therapy: The independent consumer's guide to non-toxic treatment & prevention RW Moss Equinox Press, 1992 | 67 | 1992 |
| Free radical: Albert Szent-Gyorgyi and the battle over vitamin C RW Moss Journal of the History of Biology 22 (1), 1989 | 64 | 1989 |
| Antioxidants against cancer RW Moss Equinox Press, 2000 | 50 | 2000 |
| Patient perspectives: Tijuana cancer clinics in the post-NAFTA era RW Moss Integrative cancer therapies 4 (1), 65-86, 2005 | 48 | 2005 |
| Ipilimumab (Yervoy) and the TGN1412 catastrophe T Bakacs, JN Mehrishi, RW Moss Immunobiology 217 (6), 583-589, 2012 | 47 | 2012 |
| Complete clinical remission of stage IV triple-negative breast cancer lung metastasis administering low-dose immune checkpoint blockade in combination with hyperthermia and … R Kleef, R Moss, AM Szasz, A Bohdjalian, H Bojar, T Bakacs Integrative cancer therapies 17 (4), 1297-1303, 2018 | 40 | 2018 |
| Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers–a … R Kleef, R Nagy, A Baierl, V Bacher, H Bojar, DL McKee, R Moss, ... Cancer Immunology, Immunotherapy 70 (5), 1393-1403, 2021 | 36 | 2021 |
| Complementary oncology: adjunctive methods in the treatment of cancer J Beuth, RW Moss, U Abel Thieme, 2006 | 35 | 2006 |
| Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy) T Bakacs, JN Mehrishi, M Szabó, RW Moss Pharmacological Research 66 (2), 192-197, 2012 | 25 | 2012 |
| Exploiting autoimmunity unleashed by low‐dose immune checkpoint blockade to treat advanced cancer T Bakacs, RW Moss, R Kleef, MA Szasz, CC Anderson Scandinavian Journal of Immunology 90 (6), e12821, 2019 | 24 | 2019 |
| Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies C Kerepesi, T Bakacs, RW Moss, S Slavin, CC Anderson Cancer Immunology, Immunotherapy 69 (5), 683-687, 2020 | 23 | 2020 |
| The life and times of John Beard, DSc (1858-1924) RW Moss Integrative Cancer Therapies 7 (4), 229-251, 2008 | 21 | 2008 |
| Herbs against cancer: history and controversy RW Moss Equinox Press, 1998 | 21 | 1998 |
| Response: Re: Scientific Interest in Newcastle Disease Virus Is Reviving NJ Nelson Journal of the National Cancer Institute 92 (6), 493a-494, 2000 | 20 | 2000 |
